A candidate SARS-CoV-2 vaccine from Novavax is about 90 percent effective in preventing COVID-19 in a trial conducted in the UK, the New York Times reports. However, it has an efficacy rate of less than 50 percent in a trial in South Africa, where a new viral variant has been found.